Advertisement

TMDX

TransMedics Group, Inc.

Healthcare · USD

Set alert

Price alert · TMDX

All alert types
65.99 USD -1.13 -1.68%
As of Oct 30, 2026 Extended hours 66.63 +0.98%
Bid
65.89 × 2
Ask
66.01 × 2
64.64 Day range 67.75
62.04 52-week range 150.42
YTD
-45.75%
1 year
-51.40%
Open
67.75
Prev close
67.12
Mkt cap
2.29B
Vol
900.11K
Avg vol
831.77K
EPS
3.86
P/E
17.10
Div yield
0.00%
More statistics
Low
64.64
High
67.75
Forward P/E
29.35
Beta
1.93
Short ratio
11.14
Inst. own
103.40%
Dividend
0.00
Ex-div date
Earnings
Nov 5, 2026
50-d avg
82.15
200-d avg
94.86
1y target
98.73

5D chart

Chart tools
Interval
TMDX five-day price chart64.666.568.370.172.0Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
2.29B
Enterprise value
2.72B
Trailing P/E
17.14
Forward P/E
29.35
PEG ratio
0.57
Price / sales
3.43
Price / book
4.42
EPS (TTM)
3.86
Beta
1.93
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
22.69%
Revenue (TTM)
668.47M
Revenue growth
20.70%
Free cash flow
44.50M
Total cash
472.68M
Total debt
867.72M
Return on equity
36.29%
Shares outstanding
34.68M
Short % of float
39.37%
50-day average
82.15
200-day average
94.86

Analyst view

Consensus: buy

Buy
Price target (mean) 98.73 +49.6% upside
Target (low)
65.00
Target (mean)
98.73
Target (high)
125.00
Ratings (0m) 13 9 buy · 4 hold · 0 sell
  • Strong buy3
  • Buy6
  • Hold4
  • Sell0
  • Strong sell0

Next earnings

Nov 5, 2026

Expected Nov 5, 2026. Consensus EPS estimate 0.2934.

Earnings history

Financials — quick view

All financials
TMDX Revenue — quarterly 189.95M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
TMDX Net income — quarterly 14.68M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
TMDX EPS — quarterly 0.42
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

TMDX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 20260.2976———
Aug 4, 2026Jun 30, 20260.49550.44-0.06-11.20%
May 5, 2026Mar 31, 20260.620.30-0.32-51.61%
Feb 24, 2026Dec 31, 20250.410.57+0.16+39.02%
Oct 29, 2025Sep 30, 20250.370.66+0.29+78.38%
Jul 30, 2025Jun 30, 20250.480.92+0.44+91.67%

Upgrades / downgrades

TMDX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 13, 2026Canaccord GenuitymainBuyBuy
Oct 7, 2026Barclaysinit—Overweight
Sep 8, 2026TD CowenreitBuyBuy
Aug 5, 2026UBSmainNeutralNeutral
Aug 5, 2026Piper SandlerreitOverweightOverweight
Aug 3, 2026NeedhammainBuyBuy

About TransMedics Group, Inc.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on TMDX — it syncs with the Stock Master app.

Insider holders

TMDX insider holders
InsiderRelationLatest transactionDateShares held
CECERE GIOVANNIOfficerStock Award(Grant)Feb 17, 202619,057
CORCORAN NICHOLASOfficerStock Award(Grant)Jul 9, 202641,558
FORSYTH MATTHEW SGeneral CounselStock Award(Grant)May 18, 202615,409
GUNDERSON THOMAS JAMESDirectorSaleJun 14, 202616,642
HASSANEIN WALEED HChief Executive OfficerStock Award(Grant)Jul 9, 2026666,102
HERNANDEZ GERARDOChief Financial OfficerStock Award(Grant)Jul 9, 202631,935

Institution ownership

TMDX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.16.19%5,596,549370.21MJun 29, 2026
FMR, LLC14.85%5,133,328339.57MJun 29, 2026
Vanguard Portfolio Management LLC5.60%1,933,989127.93MJun 29, 2026
Vanguard Capital Management LLC4.33%1,497,60099.07MJun 29, 2026
State Street Corporation4.11%1,420,42193.96MJun 29, 2026
Nomura Asset Management International Inc2.63%910,49560.23MJun 29, 2026

Fund ownership

TMDX fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.97%2,064,603136.57MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.01%1,038,89068.72MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.56%885,08358.55MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.18%752,16849.76MJun 29, 2026
Fidelity Securities Fund-Fidelity Small Cap Growth Fund2.10%726,13048.03MJul 30, 2026
Delaware Group Equity Funds V-Nomura Small Cap Core Fund1.79%617,37740.84MMay 30, 2026
Advertisement